Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Down 92.5% in February

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 74,900 shares, a drop of 92.5% from the January 31st total of 993,200 shares. Based on an average daily trading volume, of 397,700 shares, the short-interest ratio is currently 0.2 days. Currently, 3.7% of the shares of the company are short sold.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Analysts Set New Price Targets

APTO has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Aptose Biosciences in a research note on Wednesday, February 12th. StockNews.com began coverage on Aptose Biosciences in a research report on Tuesday. They set a “hold” rating on the stock.

Aptose Biosciences Trading Down 4.4 %

Shares of NASDAQ:APTO traded down $0.16 during midday trading on Thursday, hitting $3.48. The stock had a trading volume of 48,469 shares, compared to its average volume of 328,531. Aptose Biosciences has a 1 year low of $3.11 and a 1 year high of $58.18. The company has a market capitalization of $223.76 million, a PE ratio of -1.17 and a beta of 0.88. The stock has a 50 day moving average price of $6.06 and a two-hundred day moving average price of $8.95.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.